Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include: ...

Helping Libtayo reach its potential was a 2022 nod to treat newly diagnosed non-small cell lung cancer (NSCLC), allowing it to compete with Merck’s powerhouse PD-1 drug Keytruda. More growth ...

The approval of Libtayo (cemiplimab) in advanced NSCLC is for first-line treatment of patients with 50% or more PD-L1 expression and no EGFR, ALK or ROS1 aberrations, taking the drug into a large ...

EMPOWER-Lung-3 enrolled subjects with both squamous and non-squamous tumours and all PD-L1 expression levels, so Libtayo's efficacy comes against a more heterogenous patient population.

More cautious investors may consider this a stock for a watch-list, waiting for revenue growth to materialize as EYLEA sales stabilize, while LIBTAYO and DUPIXENT accumulate sales growth moving ...

THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more standard-of-care regimens.

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo ® (cemiplimab ... Treatment options are also more limited in advanced stages.

A ~$4.5B share repurchase program adds further value. LIBTAYO demonstrated massive growth, accelerating to 50% in Q4 2024 versus Q4 2023. Approval in CSCC means that this growth catalyst is ...

Regeneron Pharmaceuticals has shared positive results from a late-stage trial of Libtayo (cemiplimab) in patients with high-risk cutaneous squamous cell carcinoma (CSCC) after surgery. The phase 3 ...

Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...